Drug company ProStrakan considers takeover approach

Pills ProStrakan says it is "beginning to evaluate" approaches for the company

Related Stories

Drug firm ProStrakan said it has had a number of approaches to buy it.

The Galashiels manufacturer has rejected one offer from the Dutch group Norgine but was "beginning to evaluate" other approaches.

Shares in ProStrakan suffered after delays in the US of a pain relief drug, Abstral, and manufacturing problems of its anti-nausea patch Sancuso.

However despite its problems, the company said total revenue for the past 10 months rose by 20% to £76.8m.

ProStrakan said it had rebuffed a takeover approach from the Amsterdam-based pharmaceutical company Norgine because it undervalued the company.

Earlier this month Norgine snapped up an eighth of the Borders firm when it bought shares from another major company in the sector, Sanofi-Aventis.

ProStrakan's acting chief executive Peter Allen said: "The last few months have been interesting and challenging."

He added: "We fully expect that the manufacturing issues with Sancuso and the approval of Abstral in the US will be concluded this year so that revenues from both products will start early in the New Year."

More on This Story

Related Stories

The BBC is not responsible for the content of external Internet sites

More Scotland business stories

RSS

Features

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.